切换至 "中华医学电子期刊资源库"

中华介入放射学电子杂志 ›› 2022, Vol. 10 ›› Issue (01) : 70 -74,87. doi: 10.3877/cma.j.issn.2095-5782.2022.01.013

综述

上腔静脉综合征的诊疗进展
刘超1, 丁鹏绪1, 周朋利1, 韩新巍1,()   
  1. 1. 450052 河南郑州,郑州大学第一附属医院介入科
  • 收稿日期:2021-04-29 出版日期:2022-02-25
  • 通信作者: 韩新巍

Recent progress in the diagonsis and treatment of superior vena cava syndrome

Chao Liu1, Pengxu Ding1, Pengli Zhou1, Xinwei Han1,()   

  1. 1. Department of Intervention, the First Affifiliated Hospital of Zhengzhou University, Henan Zhengzhou 450052, China
  • Received:2021-04-29 Published:2022-02-25
  • Corresponding author: Xinwei Han
引用本文:

刘超, 丁鹏绪, 周朋利, 韩新巍. 上腔静脉综合征的诊疗进展[J]. 中华介入放射学电子杂志, 2022, 10(01): 70-74,87.

Chao Liu, Pengxu Ding, Pengli Zhou, Xinwei Han. Recent progress in the diagonsis and treatment of superior vena cava syndrome[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2022, 10(01): 70-74,87.

上腔静脉综合征是各种原因引起的完全或不完全性上腔静脉及其主要属支回流受阻所致的一组临床症候群,也是肿瘤科临床常见的急症。当患者出现急性或亚急性呼吸困难、面颈部肿胀,如不及时干预,进一步发展可导致缺氧、颅压增高,甚至死亡。随着时代变迁,上腔静脉综合征病因已发生很大变化,其诊断及治疗方法也随着医学技术的进步而发展。文章就上腔静脉综合征病因、临床表现、诊断及治疗做一综述。

Superior vena cava syndrome (SVCS) is a group of clinical symptoms caused by complete or incomplete obstruction of superior vena cava and its main branches. SVCS is a common tumor emergency. When the patient has acute or subacute dyspnea, face and neck swelling, if not timely intervention, can lead to hypoxia, increased intracranial pressure, and even death. With the change of the times, the etiologies of SVCS have changed greatly, and its diagnosis and treatment methods have also developed with the progress of medical technology. This article reviews the etiologies, clinical manifestations, diagnosis and treatments of SVCS to provide a better understanding.

表1 Stanford-Doty上腔静脉阻塞类型
表2 SVCS主要临床症状
表3 SVCS临床分级
[1]
Hunter W. The history of an aneurysm of the aorta with some remarkson aneurysms in general[J]. Med Obs Soc Phys Lond, 1757, 1: 323.
[2]
Klein-Weigel PF, Elitok S, Ruttloff A, et al. Superior vena cava syndrome[J]. Vasa 2020, 49(6): 437-448.
[3]
Bilyeu JA. Superior vena cava syndrome[J]. J Insur Med, 2001, 33: 349.
[4]
Herscovici R, Szyper-Kravitz M, Altman A, et al. Superior vena cava syndrome: changing etiology in the third millennium[J]. Lupus, 2012, 21: 93-96.
[5]
Uberoi R. Quality assurance guidelines for superior vena cava stenting in malignant disease[J]. Cardiovasc Intervent Radiol, 2006, 29: 319-322.
[6]
Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review[J]. Clin Oncol (R Coll Radiol), 2002, 14(5): 338-351.
[7]
Straka C, Ying J, Kong FM, et al. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome[J]. Springerplus, 2016, 5:229.
[8]
Friedman T, Quencer KB, Kishore SA, et al. Malignant venous obstruction: superior vena cava syndrome and beyond[J]. Semin Intervent Radiol, 2017, 34: 398-408.
[9]
Lazzarino M, Orlandi E, Paulli M, et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features[J]. J Clin Oncol, 1993, 11(12): 2306-2313.
[10]
Ni R, Amr M, Kalla A. Hodgkin lymphoma-associated superior vena cava syndrome: a case of report and review of the literature[J]. Am J Case Rep, 2021, 22:e929437.
[11]
Arora Y, Carrillo RG. Lead-related superior vena cava syndrome: management and outcomes[J]. Heart Rhythm, 2021, 18(2):207-214.
[12]
Stanford W, Doty DB. The role of venography and surgery in the treatment of patients with superior vena cava obstruction[J]. Ann Thorac Surg, 1986, 41(2): 158-163.
[13]
Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology[J]. Medicine (Baltimore), 2006, 85(1): 37-42.
[14]
Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome--a proposed classification system and algorithm for management[J]. J Thorac Oncol, 2008, 3(8): 811-814.
[15]
Sheth S, Ebert MD, Fishman EK. Superior vena cava obstruction evaluation with MDCT[J]. Am J Roentgenol, 2010, 194(9): W345-W346.
[16]
Kim HC, Chung SH, Park SH, et al. Systemic to pulmonary vena shunt in superior vena cava obstruction: depiction on computed tomography venography[J]. Acta Radiol, 2004, 45(3): 269-274.
[17]
Yoel S, Erica S. Prevalence and etiology of focal liver opacification in patients with superior vena cava obstruction[J].J Comput Assist Tomogr, 2013, 37: 805-808.
[18]
Loeffler JS, Leopold KA, Recht A, et al. Emergency prebiopsy radiation for mediastinal masses: impact on subsequent pathologic diagnosis and outcome[J]. J Clin Oncol, 1986, 4(5): 716-721.
[19]
Koegelenberg CF, Bolliger CT, Plekker DP, et al. Diagnostic yield and safety of ultrasound-assisted biopsies in superior vena cava syndrome[J]. Eur Respir J, 2009, 33: 1389-1395.
[20]
Pop D, Venissac N, Nadeemy AS, et al. Video-assisted mediastinoscopy in superior vena cava obstruction: to fear or not to fear?[J]. J Thorac Oncol, 2012, 7(2): 386-389.
[21]
Zimmerman S, Davis M. Rapid fire: superior vena cava syndrome[J]. Emerg Med Clin North Am, 2018, 36: 577-584.
[22]
Gloviczki P, Pairolero P, McKusick M, et al. Surgical treatment of superior vena cava syndrome//Gloviczki P, Yao J, eds. Handbook of venous disorders (2nd ed)[M]. London: Arnold; 2001: 408-417.
[23]
熊刚, 杨康, 廖克龙, 等. 血管切除重建治疗癌性上腔静脉综合征[J]. 第三军医大学学报, 2005, 27(24): 2450-2452.
[24]
Ahmann FR. A reassessment of the clinical implications of the superior vena caval syndrome[J]. J Clin Oncol, 1984, 2:961-969.
[25]
Nicholson AA, Ettles DF, Arnold A, et al. Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy[J]. J Vasc Interv Radiol, 1997, 8(5): 781-788.
[26]
Sato Y, Inaba Y, Yamaura H, et al. Malignant inferior vena cava syndrome and congestive hepatic failure treated by venous stent placement[J]. J Vasc Interv Radiol, 2012, 23(10): 1377-1380.
[27]
Van Putten JW, Schlosser NJ, Vujaskovic Z, et al. Superior vena cava obstruction caused by radiation induced venous fibrosis[J]. Thorax, 2000, 55(3): 245-246.
[28]
Pereira JR, Martins CJ, Ikari FK, et al. Neoadjuvant chemotherapy vs. radiotherapy alone for superior vena cava syndrome (SVCS) due to non-small cell lung cancer (NSCLC): preliminary results ofa randomized phase II trial[J]. Eur J Cancer, 1999, 35(Suppl 4): 260.
[29]
Scalese MJ, Hayes SL, Lott S. Antithrombotic therapy post endovascular stenting for superior vena cava syndrome[J]. Hosp Pharm, 2017, 52(10): 666.
[30]
Haddad MM, Thompson SM, McPhail IR, et al. Is long-term anticoagulation required after stent placement for benign superior vena cava syndrome?[J]. J Vasc Interv Radiol, 2018, 29(12):1741-1747.
[31]
Kalra M, Sen I, Gloviczki P. Endovenous and operative treatment of superior vena cava syndrome[J]. Surg Clin North Am, 2018, 98(2): 321-335.
[32]
Wei S, Liu J, Li X, et al. A retrospective stenting study on superior vena cava syndrome caused by lung cancer[J]. Thorac Cancer, 2020, 11(7): 1835-1839.
[33]
Straka C, Ying J, Kong FM, et al. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome[J]. Springerplus, 2016, 5: 229.
[34]
Matthaiou N, Galanakis N, Kehagias E, et al. Endovascular treatment of malignant superior vena cava syndrome through upper-limb access: a comparison between venous-dedicated and conventional stents[J].J Vasc Interv Radiol, 2020, 31(12): 2066-2072.
[35]
Fagedet D, Thony F, Timsit JF, et al. Endovascular treatment of malignant superior vena cava syndrome: results and predictive factors of clinical efficacy[J]. Cardiovasc Intervent Radiol, 2013, 36: 140-149.
[36]
Da Ines D, Chabrot P, Motreff P, et al. Cardiac tamponade after malignant superior vena cava stenting: two case reports and brief review of the literature[J]. Acta Radiol, 2010, 51: 256-259.
[37]
Siani A, Marcucci G, Accrocca F, et al. Endovascular central venous stenosis treatment ended with superior vena cava perforation, pericardial tamponade, and exitus[J]. Ann Vasc Surg, 2012, 26: 733.e9-12.
[38]
Martin M, Baumgartner I, Kolb M, et al. Fatal pericardial tamponade after Wallstent implantation for malignant superior vena cava syndrome[J]. J Endovasc Ther, 2002, 9: 680-684.
[39]
Sun K, Batra R, Markin NW, et al. Transesophageal echocardiogram-guided stent placement in superior vena cava syndrome secondary to granulomatous lung disease: a case series and literature review[J]. Vasc Endovascular Surg, 2017, 51(8): 562-566.
[1] 韩丹, 王婷, 肖欢, 朱丽容, 陈镜宇, 唐毅. 超声造影与增强CT对儿童肝脏良恶性病变诊断价值的对比分析[J]. 中华医学超声杂志(电子版), 2023, 20(09): 939-944.
[2] 郏亚平, 曾书娥. 含鳞状细胞癌成分的乳腺化生性癌的超声与病理特征分析[J]. 中华医学超声杂志(电子版), 2023, 20(08): 844-848.
[3] 燕速, 霍博文, 徐惠宁. 4K荧光腹腔镜扩大右半结肠CME+D3根治术及No.206、No.204组淋巴结清扫术[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 14-14.
[4] 姚宏伟, 魏鹏宇, 高加勒, 张忠涛. 不断提高腹腔镜右半结肠癌D3根治术的规范化[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 1-4.
[5] 杜晓辉, 崔建新. 腹腔镜右半结肠癌D3根治术淋巴结清扫范围与策略[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 5-8.
[6] 周岩冰, 刘晓东. 腹腔镜右半结肠癌D3根治术消化道吻合重建方式的选择[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 9-13.
[7] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[8] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[9] 张焱辉, 张蛟, 朱志贤. 留置肛管在中低位直肠癌新辅助放化疗后腹腔镜TME术中的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 25-28.
[10] 李凤仪, 李若凡, 高旭, 张超凡. 目标导向液体干预对老年胃肠道肿瘤患者术后血流动力学、胃肠功能恢复的影响[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 29-32.
[11] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[12] 钱龙, 陆晓峰, 王行舟, 杜峻峰, 沈晓菲, 管文贤. 神经系统调控胃肠道肿瘤免疫应答研究进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 86-89.
[13] 曹长青, 郭新艳, 高源, 张存, 唐海利, 樊东, 杨小军, 张松, 赵华栋. 肿瘤微环境参与介导HER2阳性乳腺癌曲妥珠单抗耐药的研究进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 90-95.
[14] 徐军, 姬园园, 陈君平, 王健. 伴菊形团结构的脑膜瘤合并颅骨侵犯一例并文献复习[J]. 中华临床医师杂志(电子版), 2023, 17(08): 916-919.
[15] 王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
阅读次数
全文


摘要